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Association between Painful Physical Symptoms and 
Clinical Outcomes in Korean Patients with Major 
Depressive Disorder: A Three-Month Observational Study 
 
 
 
ObjectiveaaThis paper aims to examine the association between painful physical symp-
toms (PPS) and major depressive disorder (MDD) in a naturalistic clinical practice set-
ting within a Korean population. 
MethodsaaPatients with acute MDD that joined a multicountry, observational, three-month 
study in six Asian countries and regions were classified as PPS+ (mean score ≥2) and PPS- 
(mean score <2) using the modified Somatic Symptom Inventory. In this analysis, we re-
port the results from the Korean subset, where depression severity was assessed using the 
Clinical Global Impression of Severity (CGI-S) scale and 17-item Hamilton Depression 
Rating Scale (HAMD17). Pain severity was measured using a visual analogue scale (VAS), 
while the EuroQoL (EQ-5D) assessed patient well-being. 
ResultsaaOf 198 patients, 45.96% (91/198) of patients were classified as PPS+, of which 
78.02% (71/91) were women. PPS+ patients had significantly more severe depression at 
baseline {CGI-S score, mean [standard deviation (SD)], PPS+: 5.09 [0.79]; PPS-: 4.63 
[0.76]; p<0.001; HAMD17 total score, mean [SD], PPS+: 24.34 [5.24]; PPS-: 20.76 [5.12]; 
p<0.001} and poorer quality of life [EQ-5D overall health state, mean (SD), PPS+: 39.37 
(20.52); PPS-: 51.27 [20.78]; p<0.001] than PPS- patients. Both groups improved signifi-
cantly (p<0.001) in depression and pain severity outcomes, as well as quality of life by end-
point, but no significant within-group baseline-to-endpoint change wase observed. 
ConclusionaaThe frequency of PPS was common in Korean patients with MDD, and was 
associated with more severe depression, poorer quality of life, and a trend towards poorer 
clinical outcome.   Psychiatry  Invest  2009;6:255-263
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Introduction 
 
Major depressive disorder (MDD) currently affects an estimated 340 million peo-
ple worldwide.
1 In recent years, the point prevalence of MDD among Koreans has
been rising in all age groups.
2 A 2007 study reported the 12-month prevalence of 
MDD among Koreans to be 1.7% with a lifetime prevalence of 4.3%, and roughly
twice the rate in women.
3 
Researchers speculate that the incidence of new cases of depression is currently
underestimated,
7 where underlying psychological symptoms may be masked by the 
higher incidence of concomitant painful physical symptoms (PPS), especially in 
Asian cultures. In these cultures, patients tend to somatize instead of openly ex-
pressing their emotional suffering and then seek somatic treatment.
8-11 
Kirmayer
12 stated that culture carries great influence on the expression of an indi-
vidual’s mental health or illness. Other researchers have also speculated that ethni- 
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city may influence the somatic and psychiatric occurence 
of depression.
13,14 For example, in Korean immigrant 
culture within the USA, when compared to other cul-
tures, Koreans are less likely to seek medical attention for 
anxiety, depression or other psychological problems,
15 
most likely given their strong belief that depression is a 
normal part of life rather than a mental illness.
11,16  
Depression accompanied by painful physical sym-
ptoms is also not unfamiliar to Koreans. Although con-
troversial, it has been suggested that a Korean folk syn-
drome termed “hwa-byung”, is a culturally patterned way 
that some Koreans experience depression.
17 Hwa-byung 
is thought to stem from suppressed emotions, manifest-
ing as hostility, a sense of misery, and accompanied by 
somatic symptoms
15,18-21 such as nonspecific gastroin-
testinal problems and generalized aches and pains.
22 Re-
search from other cultures reports that PPS, including 
headaches, stomach pain, back pain and vague, poorly 
localized pain, are reported by up to 76% of all patients 
with depression.
7,23-25  
High prevalence of PPS in depressed patients has been 
established in American,
24 European,
26 and Latin Ameri-
can
25 general and psychiatric practice settings, as well as 
Asian psychiatric settings.
27 This paper examines PPS in 
Korean patients with MDD in psychiatric outpatient 
settings. 
This analysis is part of a larger study covering 6 Asian 
countries/regions, with the primary objective of evaluat-
ing the frequency of PPS in Asian patients treated for an 
acute MDD episode in a naturalistic clinical practice set-
ting. Here we report the frequency of PPS in the Korean 
subpopulation and provide clinical information from a 
Korean perspective, describing the changes in disease se-
verity, treatment patterns, and quality of life observed dur-
ing the 3-month observational period. We then compare 
participant outcomes based on the presence (PPS+) or 
absence (PPS-) of painful physical symptoms. 
 
Methods 
 
Patients 
Female and male psychiatric inpatients or outpatients 
who were older than 18 years of age, with a primary di-
agnosis of MDD [Diagnostic and Statistical Manual of 
Mental Disorders, Fourth Edition Text Revision (DSM-
IV-TR)28 or the International Classification of Diseases, 
Tenth Revision (ICD-10)29], Clinical Global Impress-
ions of Severity (CGI-S) Scale ≥430 and who agreed to 
receive antidepressant treatment, were enrolled at the 
discretion of their treating psychiatrist. Patients were en-
rolled from 7 medical centers including 6 university hos-
pitals throughout Korea. 
Patients were not eligible for enrollment if they had 
any previous or current diagnosis of schizophrenia, schi-
zophreniform disorder, schizoaffective disorder, bipolar 
disorder or dementia. Patients were also excluded from 
the study if their current depressive episode had persisted 
for ≥6 months, if they were experiencing treatment-re-
sistant chronic pain or had a painful inflammatory con-
dition related to an identifiable medical condition. 
 
Study design 
This prospective, non-interventional, epidemiological, 
three-month observational study was designed to assess 
the frequency of PPS occurrence among patients from 6 
Asian countries/regions treated in naturalistic clinical set-
tings for an acute episode of MDD. Patients were re-
cruited from 14 June 2006 to 15 February 2007. We now 
present data from a subanalysis of all Korean patients 
who completed both baseline and endpoint visits.   
Treatment for MDD was prescribed through the usual 
standard of care by the treating physician, and was not 
provided or directed by the study sponsor. All subsequ-
ent treatment changes were solely at the discretion of the 
physician and the patient, and there was no attempt by 
the sponsor to influence prescribing patterns.   
Upon joining the study entry, patients were assessed 
for the presence of PPS as measured by their mean score 
on the pain related items of the modified Somatic Sym-
ptom Inventory (SSI)[items 27 (joint pain) and 28 (neck 
pain) were added].
31 Patients with a mean score of ≥2 
were defined as painful physical symptom positive (PPS+) 
and the remaining patients were defined as painful phy-
sical symptom negative (PPS-). The SSI items are rated 
on a scale of 1 to 5; 1 is defined as “not at all” and 2 to 
5 indicate presence of symptoms in increasing severity.
32 
Following enrollment, patients were observed for three 
months. To collect data during the study, there was a total 
of two visits, at baseline and study end. Upon entering 
the study, patients were assessed for eligibility and con-
sent to release information was received from each pa-
tient or their legal representative prior to enrolment.   
This study was not designed to assess the overall sa-
fety profile of any study drug. The study investigators 
had an obligation to report any spontaneous treatment-
emergent adverse events and serious adverse events, just 
as they would in normal clinical practice.   
The study protocol (study code: F1J-AA-B015) was 
submitted to and subsequently approved by the local re-
gulatory agency as well as each institutional review board. 
This study was carried out in accordance with the ethical 
principles that have their origin in the Declaration of Hel-
sinki. These principles are also consistent with good clini-
cal practices in addition to Korean laws and regulations.  
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Measures 
Demographic and clinical data, including disease his-
tory, work, hospitalization and medical comorbidities, 
were collected at baseline. Clinical data was also collect-
ed at endpoint. Depression severity was measured using 
the 17-item Hamilton Depression Rating Scale (HA-
MD17)33 and CGI-S. Response was defined as a ≥50% 
reduction in HAMD17 total score from baseline to end-
point. Remission was defined by a HAMD17 total score 
of ≤7 at endpoint. Pain severity was measured using a 
Visual Analog Scale (VAS)34 and patient quality of life 
was assessed using the EuroQol Questionnaire-5 Di-
mensions (EQ-5D). The EQ-5D is a self-administered 
questionnaire that provides a utility score related to he-
alth state and impact on usual life activities including 
mobility, self-care, usual activities, pain/discomfort and 
anxiety/depression. A set of weights that represent the 
general population’s preferences is employed to create 
the index.
35 For the EQ-5D scale, a United Kingdom po-
pulation was used to standardize scores as a Korean po-
pulation has not been validated. 
 
Statistical analysis 
The primary analytical objective for this study, to es-
timate the frequency of PPS within the full study cohort, 
has been previously reported.
27 Demographic character-
istics and treatment patterns of patients were evaluated 
across PPS groups using: 1) two-sample t-test or nonpa-
rametric Wilcoxon rank sum test for continuous vari-
ables, 2) Fisher’s exact test for categorical variables and 
3) analysis of covariance (ANCOVA) for changes from 
baseline on clinical outcome variables (HAMD17, CGI-S, 
VAS and EQ-5D) adjusted for propensity scores. In this 
study the propensity score represents the conditional pro-
bability of a patient being PPS+ given their baseline data. 
The propensity score was calculated with a logistic re-
gression model using the following baseline variables 
defined a priori: gender, age, age at first episode, illness 
severity, previous depressive episodes (yes/no), number 
of previous depressive episodes, number of significant 
pre-existing comorbidities and previous depression treat-
ment (drug and non-drug). In this study, the propensity 
score represents the conditional probability of a patient 
being PPS+ given their baseline data. Further interaction 
terms determined post hoc included CGI-S with EQ-5D, 
SSI with VAS and EQ-5D with number of significant pre-
existing comorbidities.
36 
Comparisons between selective serotonin reuptake 
inhibitor (SSRI) and serotonin and norepinephrine reup-
take inhibitor (SNRI) monotherapy groups were eval-
uated at baseline and for changes from baseline (adjusted 
for baseline, age and sex). Logistic regression was used 
to evaluate the number of patients achieving response 
and remission, with comparisons made between PPS 
groups  (adjusted for propensity scores). All statistical 
analyses were performed using SAS
® Version 8.2 for 
Windows
TM (SAS Institute, Cary, NC). No adjustment 
for multiple comparisons was performed. The level of st-
atistical significance was defined a priori as alpha=0.05. 
 
Results 
 
Patient disposition 
A total of 198 patients were enrolled in Korea, of 
which 46.0% (91/198) were PPS+ and 54.0% (107/198) 
were PPS-. The overall completion rate in the study was 
74.2% (147/198), with 71.4% (65/91) of completers in 
the PPS+ group and 76.6% (82/107) of completers in 
the PPS- group. Forty-eight patients were lost to follow-
up [28.6% (26/91) PPS+ patients and 20.6% (22/107) 
PPS- patients]. In the PPS- group, two patients volunta-
rily discontinued and one patient committed suicide dur-
ing the study. There were no statistically significant bet-
ween-group differences regarding reasons for disconti-
nuation. 
 
Demographic and disease characteristics at 
baseline 
The demographic and disease characteristics of PPS+ 
and PPS- patients at baseline are detailed in Table 1. 
Significantly more patients in both groups were women 
[overall: 68.7% (136/198), p=0.009]. Patients had a mean 
[standard deviation (SD)] age of 49.5 (14.17) years and 
a mean body mass index (BMI)(SD) of 22.9 (3.05) kg/m
2. 
Overall, patients experienced their first depressive epi-
sode at the mean age (SD) of 46.5 (14.1) years, 35.9% 
(66/184) of patients had one or more previous depres-
sive episodes with a mean (SD) episode duration of 11.4 
(10.14) weeks. In the PPS+ group, the mean (SD) durat-
ion of the current depressive episode was 8.7 (7.83) 
weeks, while in the PPS- group it was 7.6 (5.84) weeks, 
but not statistically significant. The most frequently re-
ported medical comorbidities were cardiovascular disease 
[PPS+: 15.4% (14/91); PPS-: 16.8% (18/107)], diabetes 
mellitus [PPS+: 8.8% (8/91); PPS-: 6.5% (7/107)] and 
gastrointestinal disease [PPS+: 7.7% (7/91); PPS-: 7.5% 
(8/107)]. 
 
Depression measures 
At baseline, PPS+ was associated with significantly 
greater severity of depression and poorer clinical status 
than PPS- based on CGI-Severity score [PPS+ Mean 
(SD): 5.1 (0.79); PPS-: 4.6 (0.76); p<0.001], HAMD17 
total score [PPS+ Mean (SD): 24.3 (5.24): PPS-: 20.8  
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(5.12); p<0.001], HAMD anxiety/somatization [PPS+ 
Mean (SD): 8.7 (2.44); PPS-: 7.5 (2.90); p=0.006] and 
HAMD core mood subscores [PPS+ Mean (SD): 8.7 
(2.96); PPS-: 7.5 (2.45); p=0.007](Table 1). From base-
line to endpoint, there was a statistically significant (p< 
0.001) improvement in all depression severity measures 
in both PPS+ and PPS- patients (adjusted mean change 
from baseline to endpoint) (Figures 1 and 2); no signi-
ficant between-group differences were found. There were 
no statistically significant differences between groups in 
terms of the proportion of responders or remitters at end-
point [difference in response (PPS+ minus PPS-): -0.06, 
95% CI (-0.21, 0.10), p=0.487; difference in remission 
(PPS+ minus PPS-): -0.06, 95% CI (-0.22, 0.10), p= 
0.506]. 
 
Pain measures 
As expected, PPS+ patients reported significantly gr-
eater (p<0.001) pain severity at baseline than PPS- pa-
tients based on the VAS overall and subscales (Table 1). 
At endpoint, patients in both groups experienced a sig-
nificant improvement in pain severity [adjusted mean 
change from baseline; p<0.001 for PPS+ and PPS- pa-
tients on VAS overall and all subscales, except for PPS+ 
patients with shoulder pain (p=0.008)], improvement be-
ing prominent in the pain interference, pain while awake, 
and headache subscales (Figure 3). Between-group dif-
TABLE 1. Patient demographics and disease severity at baseline
 PPS+  (n=91) PPS-  (n=107) Overall  (N=198) p-value
Age, mean (SD) 50.0  (14.77) 49.2  (13.70) 49.5  (14.17)  <0.712* 
Female n, (%)  .071 (78.0)  0.65 (60.8)  .136 (68.7)  <0.009***
Body Mass Index (kg/m2), mean (SD) 22.9  (2.68) 22.9  (3.33) 22.9  (3.05)  <0.999* 
Age at first episode of MDD, mean (SD) 46.7  (14.24) 46.4  (14.13) 46.5  (14.14)  <0.900* 
Number of previous episodes, median (range)  02.0 (1.0-18.0)  02.0 (1.0-10.0)  02.0 (1.0-18.0)  <0.989** 
≥1 previous episode, n (%)  0.30 (38.0)  0.36 (34.3)  0.66 (35.9)  <0.643***
Duration of current episode, weeks, median (range)  06.0 (2.00-53.00)  06.0 (1.00-32.00)  06.0 (1.00-53.00)  <0.425** 
Last episode, weeks, median (range) 12.0  (1.00-48.00)  08.0 (2.00-52.00)  08.0 (1.00-52.00)  <0.030** 
Time between remission of last and start of current 
  episode, weeks, median (range) 
24.0 (9.00-192.00) 
 
24.0 (8.00-670.00) 
 
24.0 (8.00-670.00) 
 
<0.716** 
 
CGI-severity, mean (SD)  05.1 (0.79)  04.6 (0.76)  04.8 (0.81) <0.001* 
HAMD17 total score, mean (SD) 24.3  (5.24) 20.8  (5.12) 22.3  (5.46) <0.001* 
HAMD17 Anxiety/Somatization, mean (SD)  08.7 (2.44)  07.5 (2.90)  08.0 (2.77)  <0.006* 
HAMD17 Core mood, mean (SD)  08.7 (2.96)  07.5 (2.45)  08.0 (2.74)  <0.007* 
EQ-5D health state score, median (range) 40.0  (0-85.00) 50.0  (0-99.00) 50.0  (0-99.00)  <0.001** 
VAS, median (range)        
Overall pain  62.0 (7.0-100.00) 39.0  (0-100.00) 50.0  (0-100.00) <0.001** 
Headache 50.0  (0-100.00) 11.0  (0-93.00) 30.0  (0-100.00) <0.001** 
Back pain  38.0 (0-100.00)  04.0 (0-100.00) 10.0  (0-100.00) <0.001** 
Shoulder pain  40.0 (0-100.00)  05.0 (0-100.00) 10.0  (0-100.00) <0.001** 
Pain interference  67.0 (0-100.00) 31.5  (0-100.00) 50.0  (0-100.00) <0.001** 
Pain while awake  62.0 (0-100.0) 20.0  (0-100.0) 45.0  (0-100.0) <0.001** 
*p-value using t-test for comparison of means, **p-value using non-parametric Wilcoxon Rank Sum Test, ***p-value using Fisher’s Exact 
Test. PPS+: painful physical symptom positive group, PPS-: remainder of study population, n: number of patients in each group, N:
number of patients in the total study population, SD: standard deviation, MDD: major depressive disorder, CGI-Severity: Clinical Global 
Impressions of Severity Scale, HAMD17: 17-item Hamilton Depression Rating Scale, VAS: Visual Analog Scale, EQ-5D: EuroQol Que-
stionnaire-5 Dimensions 
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FIGURE 1. Adjusted mean change from baseline to endpoint in
CGI-S total score. 
ap-value for adjusted mean difference [0.15,
95% CI (-0.21, 0.51)] using Type III Sums of Squares from analy-
sis of covariance (ANCOVA) model: change=PPS group, propen-
sity score and baseline. *Within group p-value (p<0.001) from AN-
COVA model: change=PPS group, propensity score and baseline.
PPS+: painful physical symptom positive group, PPS-: remainder
of study population, CGI-S: Clinical Global Impressions of Seve-
rity Scale, n: number of patients in each group, CI: confidence in-
terval.  
 
 
 
 
MS Lee et al. 
www.psychiatryinvestigation.org 259 
ferences in pain severity measures from baseline to end-
point were not statistically significant (Figure 3).  
 
Quality of life measures 
At baseline, PPS+ patients had significantly (p<0.001) 
lower quality of life [EQ-5D health state score mean 
(SD): 39.4 (20.52); EQ-5D utility score mean (SD): 0.2 
(0.36)] than PPS- patients [EQ-5D health state score mean 
(SD): 51.3 (20.78); EQ-5D utility score mean (SD): 0.5 
(0.30)]. Both groups of patients had statistically signifi-
cant improvements in quality of life (p<0.001) from base-
line to endpoint {PPS+ [adjusted mean change in EQ-
5D health state score (95% CI)]: 20.9 [16.11, 25.64]; 
adjusted mean change in EQ-5D utility score [95% CI]: 
0.3 [0.27, 0.40]}{PPS- [adjusted mean change in EQ-
5D health state score (95% CI)]: 24.0 [19.78, 28.22]; ad-
justed mean change in EQ-5D utility score [95% CI]: 
0.4 [0.36, 0.47]}.  
 
Work and hospitalization 
During the three months prior to the study, 74.4% (67/ 
90) of PPS+ patients and 65.1% (69/106) of PPS- patients 
were unemployed. During the three-month study period, 
68.5% (50/73) of PPS+ patients and 67.0% (61/91) of 
PPS- patients were unemployed. Patients that did work 
during the study period worked on average a total of 40 
hours per week and did not miss a day of work due to 
MDD (range 0-9 days). 
A total of eight patients required psychiatric hospita-
lization during the study. In the PPS+ group, 7.8% of 
the patients were hospitalized, whereas 3.8% of the pa-
tients in the PPS- group were hospitalized; however, 
these results were not statistically significant. During the 
study, 4.7% of PPS+ patients and 1.3% of PPS- patients 
required 29 days or more of hospitalization. 
 
Treatment patterns  
Of 197 patients reporting treatment at study entry, 53 
patients were not receiving any treatment and 144 pa-
tients were receiving one or more treatments. There was 
no statistically significant difference between PPS+ or 
PPS- patients in terms of medication class, number, and 
psychosocial therapy. A small proportion of patients 
[11.4% (22/193)] were receiving some treatment for pain 
at baseline. More PPS+ patients [12.2% (11/90)] used one 
or more classes of concomitant treatment. 
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FIGURE 3. Adjusted mean change from
baseline to endpoint in VAS overall and
subscales. 
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difference using Type III Sums Of Squ-
ares from analysis of covariance (AN-
COVA) model: change=PPS group, pro-
pensity score and baseline. *Within gr-
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ptom positive group, PPS-: remainder
of study population, VAS: Visual Analog
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using Type III Sums Of Squares from analysis of covariance (AN-
COVA) model: change=PPS group, propensity score and base-
line. *Within group p-value (p<0.001) from ANCOVA model: ch-
ange=PPS group, propensity score and baseline, and is the same
for HAMD17 total score and both subscores that are presented
here. PPS+: painful physical symptom positive group, PPS-: re-
mainder of study population, HAMD17: 17-item Hamilton Depres-
sion Rating Scale, CI: confidence interval.  
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The most commonly prescribed antidepressants at base-
line and at endpoint were the SSRI paroxetine and esci-
talopram, followed by mirtazapine and venlafaxine. The 
most common reason for discontinuation of MDD treat-
ment was inadequate response to treatment, followed by 
the investigator’s or patient’s perception of cure. A total 
of eight patients discontinued their MDD medication due 
to an adverse event 
There was no statistically significant difference be-
tween treatments with SSRI [at baseline: PPS+ n=39 
(42.9%); PPS- n=52 (48.6%)] versus SNRI [at baseline: 
PPS+ n=15 (16.5%); PPS- n=9 (8.4%)] monotherapy 
from baseline to endpoint. This was the case in all en-
rolled patients in terms of depression severity and qu-
ality of life as measured by CGI-S, HAMD17 total score, 
HAMD17 anxiety/somatization, HAMD17 core mood and 
EQ-5D health state and utility scores. However, both 
groups of patients did experience statistically significant 
improvement in depression severity and quality of life 
with both treatments. Similar results were obtained when 
comparing both treatments based on the VAS as a pain 
severity measure. Overall, statistically significant pain 
relief was experienced by patients receiving both SSRI 
and SNRI treatments regarding overall pain, headache 
severity, pain interference and pain while awake. 
 
Discussion 
 
In this Korean subanalysis of a multicountry, three-
month, prospective, noninterventional study in Asian pa-
tients with MDD,
27 the frequency of PPS in the Korean 
subpopulation was found to be 46.0%. Although clini-
cians may assume that as a result of greater cultural ac-
ceptance, PPS are more frequent in Asians,
37,38 the ob-
servations in this study do not support this assumption. 
The frequency of PPS reported in Koreans was com-
parable to the prevalence found in Europe (43.0%),
26 
but lower than that reported in the overall Asian study 
(51.8%),
27 and even lower when compared with results 
reported in North America (69.0%)24 and Latin America 
(73.0%).
25  
PPS reporting is usually linked to reporting and in-
terpretational bias, can be culturally sensitive and also re-
flects country-specific training practices of health care 
professionals, for instance, how complaints are explored. 
Country-specific data and subanalyses can, therefore, 
help to reveal such country-specific differences, while 
cross cultural studies can indicate potential linkages be-
tween cultural values, socialization practices and sym-
ptom reporting.
39,40 Additionally, the study was conduct-
ed in university hospitals in Korea, which exist as ter-
tiary referral centers. As a result, patients treated in major 
university hospitals cannot be said to be representative 
of the MDD population in Korea. Although this study 
was carried out in patients presented to psychiatrists in 
the cultural ambience of Korea, patients with MDD and 
PPS may be more likely to present to other specialties 
with complaints of pain as opposed to psychiatrists with 
depression.  
In Korean patients with acute MDD, the presence of 
PPS at baseline was associated with a greater severity of 
depression and poorer quality of life. Similar outcomes 
were observed for the overall study and other evaluated 
Asian subpopulations evaluated.
27 By study end, both 
PPS+ and PPS- patients had improved significantly in 
terms of their depression and quality of life. There was a 
trend towards more severe depression and poorer qu-
ality of life for PPS+ patients compared to the overall 
study sample. However, no statistically significant differ-
ence in terms of depression and quality of life between 
PPS+ and PPS- patients was observed by study end. 
As the Korean patient sample was predominantly com-
prised of women who had experienced their first de-
pressive episode later in life (46.5 years of age on av-
erage) than commonly expected,
41 it is possible that these 
patients were going through perimenopausal or meno-
pausal depression, which is commonly related to PPS.
42 
Also of note was the high rate of unemployment observ-
ed in both PPS+ and PPS- patients in the three months 
prior to the study commencement and during the study 
period in this Korean sample. However, the assessment 
did not differentiate between unemployment and women 
working full time as housewives, who were also classi-
fied as unemployed. Following the financial crisis in 
1997, Korean workers no longer enjoyed lifetime em-
ployment that had previously characterized the work en-
vironment in this country.
43 Instead, Korean companies 
have enforced early retirement, honorary retirement and 
layoffs to reduce their payrolls.
43 In 2003, Jang reported 
that only 60.0% of Korean workers in their early thirties 
will still be employed by the time they become 50 years 
old.
44  
In terms of treatment, a previous study has verified 
the utility of SNRIs (duloxetine) as efficacious and safe 
treatments for emotional and physical symptoms of MDD 
in a predominantly Asian patient sample.
45 In the Kor-
ean subpopulation, no statistically significant between-
group difference in treatments were found with SSRIs 
and SNRIs. While there were no statistical differences 
between PPS+ and PPS-, the PPS+ group did show a 
trend to fare less well in their treatment. The PPS+ group 
experienced lower completion rates, higher hospitaliza-
tion rates with more stays over 29 days, more required 
classes of treatment, and less improvement in all efficacy  
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measures. Antidepressant selection patterns based on 
psychiatric symptoms with and without PPS were not 
considered in the statistical comparison, but might be 
undertaken in further analyses. 
Depressive symptoms in Korean people can be per-
ceived in a complex way, intricately overlapping in all 
domains of a person’s existence.
46 DSM-IV currently lists 
hwa-byung as a Korean culture-bound syndrome typi-
cally associated with middle-aged and elderly women 
that results from distressed emotions and passive suf-
fering. It is related specifically to the Korean way of 
perceiving and reacting to intolerable situations.
15 Fur-
thermore, it is characterized by predominantly physical 
symptoms of depression and anhedonia, generally lack-
ing subjective awareness of depressed feelings. This is 
comparable to Kohut’s concept, where affective disorders 
result from extreme fear, threat to self-esteem or worth 
and the shame of being faced with failure (narcissistic 
rage).
47 Similarly, McDougall associated the presence of 
somatic symptoms in alexithymic patients with a response 
or defense mechanism against frightening experiences.
48 
Just as depression has a complex biopsychosocial eti-
opathogenesis, perception of pain is also a complex phe-
nomenon. The subjective experience of pain results from 
central integration of painful stimuli, along with emotio-
nal and cognitive factors. It is suggested that depression 
may contribute to increased excitability of the central no-
ciceptive pathways via the limbic system input,
49,50 and 
ultimately contribute to pain sensation. Chronic pain may 
also contribute to depression. In chronic pain, the soma-
tosensory pathway is not activated, but rather the depres-
sion pathway, with signals from the limbic system. The 
kindling model has been applied to pain-induced neuro-
plastic changes and corticolimbic sensitization, leading 
to a clinical picture of persistent pain, affective dysregu-
lation and disturbances in behavior.
51 
Along with the stigma of mental illness, Koreans in 
general tend to have a greater acceptance of physical ra-
ther than mental pain. In this context, it can be specu-
lated that the frequency of PPS may be higher in Korean 
patients with MDD; however, this study cannot confirm 
or refute this hypothesis.   
Results from the overall multicountry study revealed 
that PPS are experienced by approximately half of pa-
tients with MDD in Asia and are associated with poor 
clinical status and less pain reduction.
27 The greater ad-
justed pain reduction experienced by PPS- patients may 
indicate that depression with substantial pain requires a 
different treatment strategy. This strategy would differ 
from SSRI treatment, which is what the majority of pa-
tients received. On the other hand, another possible ex-
planation for less pain reduction in the presence of so-
matic symptoms is Freud’s concept of guilt, which sus-
tains that self-flagellation, reflected in this case as the 
presence of somatic symptoms, is an expression of the 
patient’s resistance to recovery.
45 
 
Limitations 
It is important to note that the overall study of 6 
Asian countries/regions may not be powered for coun-
try-specific analyses, and therefore, data should be inter-
preted with caution. Patients without postbaseline visits 
and measures for all covariates were excluded from the 
analysis, resulting in a reduced size of the country-spe-
cific analysis population. The findings presented for this 
Korean subpopulation are for descriptive and explorative 
purposes and must be interpreted within these confines. 
Even though the gender findings were consistent with 
that of the overall study across all Asian cohorts (68.7% 
to 78.0% of patients were women who presented PPS 
with an overall onset of first depressive episode at 41.0 
years of age),
27 these elements could be potential con-
founders. The high unemployment rates observed in this 
Korean population may be more related to the Korean 
employment pattern or the higher percentage of unem-
ployed housewives, than the severity of their depression. 
This could be another confounder. Additionally, the va-
lidity of the pain scores used may not be well establi-
shed and suitably devised for all ages and genders.   
 
Conclusions 
In this study, almost half of the Korean MDD patients 
experienced PPS. As PPS has been associated with more 
severe depression, lower quality of life and a trend to-
wards poorer outcomes, clinical management should aim 
to address associated mental and physical symptoms. 
Our results support previous findings in Asia, indicating 
that the presence of PPS is associated with more severe 
depression.
27 Overall, despite the established appreci-
ation of pain perception complexities, further research is 
needed to explore the impact of such complexities on 
choices of effective treatment modalities.   
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